Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target.

Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, Patel NU, Ham J, Hu B, Powell KM, Coon CM, Windle BE, Oya Y, Koblinski JE, Harada H, Leverson JD, Souers AJ, Hata AN, Boikos S, Yatabe Y, Ebi H, Faber AC.

Clin Cancer Res. 2018 Aug 7. doi: 10.1158/1078-0432.CCR-18-0304. [Epub ahead of print]

PMID:
30087143
2.

Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC.

Sci Transl Med. 2018 May 16;10(441). pii: eaao4680. doi: 10.1126/scitranslmed.aao4680.

PMID:
29769286
3.

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.

4.

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, Konopleva M, Letai A.

Cancer Discov. 2017 Dec;7(12):1376-1393. doi: 10.1158/2159-8290.CD-17-0797. Epub 2017 Nov 16. Review.

5.

Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.

Lochmann TL, Floros KV, Naseri M, Powell KM, Cook W, March RJ, Stein GT, Greninger P, Maves YK, Saunders LR, Dylla SJ, Costa C, Boikos SA, Leverson JD, Souers AJ, Krystal GW, Harada H, Benes CH, Faber AC.

Clin Cancer Res. 2018 Jan 15;24(2):360-369. doi: 10.1158/1078-0432.CCR-17-1606. Epub 2017 Nov 8.

6.

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.

Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ.

Nat Rev Drug Discov. 2017 Apr;16(4):273-284. doi: 10.1038/nrd.2016.253. Epub 2017 Feb 17. Review.

PMID:
28209992
7.

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.

Bodo J, Zhao X, Durkin L, Souers AJ, Phillips DC, Smith MR, Hsi ED.

Oncotarget. 2016 Oct 25;7(43):70000-70010. doi: 10.18632/oncotarget.12132.

8.

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).

Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, Leverson JD.

Blood Cancer J. 2016 Mar 11;6:e403. doi: 10.1038/bcj.2016.12. No abstract available.

9.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, Young A, Mitten M, Ingalla E, Darbonne WC, Oleksijew A, Tapang P, Yue P, Oeh J, Lee L, Maiga S, Fairbrother WJ, Amiot M, Souers AJ, Sampath D.

Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.

10.

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).

Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, Leverson JD.

Blood Cancer J. 2015 Nov 13;5:e368. doi: 10.1038/bcj.2015.88. Erratum in: Blood Cancer J. 2016;6:e403.

11.

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.

Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K, McGonigal T, Mishra S, Schlessinger S, Smith ML, Tahir SK, Leverson JD, Souers AJ, Boghaert ER, Hickson J.

Pharmacol Res Perspect. 2015 Oct;3(5):e00178. doi: 10.1002/prp2.178. Epub 2015 Sep 1.

12.

Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.

Zhang H, Xue J, Hessler P, Tahir SK, Chen J, Jin S, Souers AJ, Leverson JD, Lam LT.

Mol Cancer. 2015 Jul 2;14:126. doi: 10.1186/s12943-015-0397-y.

13.

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.

Xiao Y, Nimmer P, Sheppard GS, Bruncko M, Hessler P, Lu X, Roberts-Rapp L, Pappano WN, Elmore SW, Souers AJ, Leverson JD, Phillips DC.

Mol Cancer Ther. 2015 Aug;14(8):1837-47. doi: 10.1158/1535-7163.MCT-14-0928. Epub 2015 May 26.

14.

Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.

Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, Erickson S, Fidanze S, Fry E, Hasvold L, Jenkins GJ, Jin S, Judge RA, Kovar PJ, Madar D, Nimmer P, Park C, Petros AM, Rosenberg SH, Smith ML, Song X, Sun C, Tao ZF, Wang X, Xiao Y, Zhang H, Tse C, Leverson JD, Elmore SW, Souers AJ.

J Med Chem. 2015 May 14;58(9):4089. doi: 10.1021/acs.jmedchem.5b00616. Epub 2015 May 1. No abstract available.

PMID:
25933255
15.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ.

Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.

PMID:
25787766
16.

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, Erickson S, Fidanze S, Fry E, Hasvold L, Jenkins GJ, Jin S, Judge RA, Kovar PJ, Madar D, Nimmer P, Park C, Petros AM, Rosenberg SH, Smith ML, Song X, Sun C, Tao ZF, Wang X, Xiao Y, Zhang H, Tse C, Leverson JD, Elmore SW, Souers AJ.

J Med Chem. 2015 Mar 12;58(5):2180-94. doi: 10.1021/jm501258m. Epub 2015 Feb 26. Erratum in: J Med Chem. 2015 May 14;58(9):4089.

PMID:
25679114
17.

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, Kovar P, Tanaka A, Bruncko M, Sheppard GS, Wang L, Gierke S, Kategaya L, Anderson DJ, Wong C, Eastham-Anderson J, Ludlam MJ, Sampath D, Fairbrother WJ, Wertz I, Rosenberg SH, Tse C, Elmore SW, Souers AJ.

Cell Death Dis. 2015 Jan 15;6:e1590. doi: 10.1038/cddis.2014.561.

18.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, Deshayes K, Fairbrother WJ, Flygare JA, Hymowitz SG, Jin S, Judge RA, Koehler MF, Kovar PJ, Lessene G, Mitten MJ, Ndubaku CO, Nimmer P, Purkey HE, Oleksijew A, Phillips DC, Sleebs BE, Smith BJ, Smith ML, Tahir SK, Watson KG, Xiao Y, Xue J, Zhang H, Zobel K, Rosenberg SH, Tse C, Leverson JD, Elmore SW, Souers AJ.

ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. doi: 10.1021/ml5001867. eCollection 2014 Oct 9.

19.

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Koehler MF, Bergeron P, Choo EF, Lau K, Ndubaku C, Dudley D, Gibbons P, Sleebs BE, Rye CS, Nikolakopoulos G, Bui C, Kulasegaram S, Kersten WJ, Smith BJ, Czabotar PE, Colman PM, Huang DC, Baell JB, Watson KG, Hasvold L, Tao ZF, Wang L, Souers AJ, Elmore SW, Flygare JA, Fairbrother WJ, Lessene G.

ACS Med Chem Lett. 2014 Mar 21;5(6):662-7. doi: 10.1021/ml500030p. eCollection 2014 Jun 12.

20.

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.

Petros AM, Swann SL, Song D, Swinger K, Park C, Zhang H, Wendt MD, Kunzer AR, Souers AJ, Sun C.

Bioorg Med Chem Lett. 2014 Mar 15;24(6):1484-8. doi: 10.1016/j.bmcl.2014.02.010. Epub 2014 Feb 14.

PMID:
24582986
21.

The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.

Choo EF, Boggs J, Zhu C, Lubach JW, Catron ND, Jenkins G, Souers AJ, Voorman R.

Drug Metab Dispos. 2014 Feb;42(2):207-12. doi: 10.1124/dmd.113.055053. Epub 2013 Nov 8.

22.

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.

Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, Maïga S, Béné MC, Moreau P, Pellat-Deceunynck C, Amiot M.

Leukemia. 2014 Jan;28(1):210-2. doi: 10.1038/leu.2013.216. Epub 2013 Jul 17. No abstract available.

23.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW.

Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.

PMID:
23291630
24.

Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.

Yeh VS, Beno DW, Brodjian S, Brune ME, Cullen SC, Dayton BD, Dhaon MK, Falls HD, Gao J, Grihalde N, Hajduk P, Hansen TM, Judd AS, King AJ, Klix RC, Larson KJ, Lau YY, Marsh KC, Mittelstadt SW, Plata D, Rozema MJ, Segreti JA, Stoner EJ, Voorbach MJ, Wang X, Xin X, Zhao G, Collins CA, Cox BF, Reilly RM, Kym PR, Souers AJ.

J Med Chem. 2012 Feb 23;55(4):1751-7. doi: 10.1021/jm201524g. Epub 2012 Feb 10.

PMID:
22263872
25.

Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.

Sleebs BE, Czabotar PE, Fairbrother WJ, Fairlie WD, Flygare JA, Huang DC, Kersten WJ, Koehler MF, Lessene G, Lowes K, Parisot JP, Smith BJ, Smith ML, Souers AJ, Street IP, Yang H, Baell JB.

J Med Chem. 2011 Mar 24;54(6):1914-26. doi: 10.1021/jm101596e. Epub 2011 Mar 2.

PMID:
21366295
26.

In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.

King AJ, Segreti JA, Larson KJ, Souers AJ, Kym PR, Reilly RM, Collins CA, Voorbach MJ, Zhao G, Mittelstadt SW, Cox BF.

Eur J Pharmacol. 2010 Jul 10;637(1-3):155-61. doi: 10.1016/j.ejphar.2010.03.056. Epub 2010 Apr 10.

PMID:
20385122
27.

Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents.

King AJ, Judd AS, Souers AJ.

Expert Opin Ther Pat. 2010 Jan;20(1):19-29. doi: 10.1517/13543770903499305. Review.

PMID:
20021283
28.

Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster.

King AJ, Segreti JA, Larson KJ, Souers AJ, Kym PR, Reilly RM, Zhao G, Mittelstadt SW, Cox BF.

J Pharmacol Exp Ther. 2009 Aug;330(2):526-31. doi: 10.1124/jpet.109.154047. Epub 2009 May 28.

29.

Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.

Judd AS, Souers AJ, Kym PR.

Curr Top Med Chem. 2008;8(13):1152-7. Review.

PMID:
18782010
30.

Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.

Zhao G, Souers AJ, Voorbach M, Falls HD, Droz B, Brodjian S, Lau YY, Iyengar RR, Gao J, Judd AS, Wagaw SH, Ravn MM, Engstrom KM, Lynch JK, Mulhern MM, Freeman J, Dayton BD, Wang X, Grihalde N, Fry D, Beno DW, Marsh KC, Su Z, Diaz GJ, Collins CA, Sham H, Reilly RM, Brune ME, Kym PR.

J Med Chem. 2008 Feb 14;51(3):380-3. doi: 10.1021/jm7013887. Epub 2008 Jan 10.

PMID:
18183944
31.

Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists.

Kym PR, Judd AS, Lynch JK, Iyengar R, Vasudevan A, Souers AJ.

Curr Top Med Chem. 2007;7(15):1471-88. Review.

PMID:
17897033
32.

Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.

Judd AS, Souers AJ, Wodka D, Zhao G, Mulhern MM, Iyengar RR, Gao J, Lynch JK, Freeman JC, Falls HD, Brodjian S, Dayton BD, Reilly RM, Gintant G, Limberis JT, Mikhail A, Leitza ST, Houseman KA, Diaz G, Bush EN, Shapiro R, Knourek-Segel V, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2365-71. Epub 2006 Dec 1.

PMID:
17350253
33.

An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.

Iyengar RR, Lynch JK, Mulhern MM, Judd AS, Freeman JC, Gao J, Souers AJ, Zhao G, Wodka D, Doug Falls H, Brodjian S, Dayton BD, Reilly RM, Swanson S, Su Z, Martin RL, Leitza ST, Houseman KA, Diaz G, Collins CA, Sham HL, Kym PR.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):874-8. Epub 2006 Dec 1.

PMID:
17234405
34.

Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.

Souers AJ, Iyengar RR, Judd AS, Beno DW, Gao J, Zhao G, Brune ME, Napier JJ, Mulhern MM, Lynch JK, Freeman JC, Wodka D, Chen CJ, Falls HD, Brodjian S, Dayton BD, Diaz GJ, Bush EN, Shapiro R, Droz BA, Knourek-Segel V, Hernandez LE, Marsh KC, Reilly RM, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):884-9. Epub 2006 Dec 1.

PMID:
17188866
35.

Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety.

Basso AM, Bratcher NA, Gallagher KB, Cowart MD, Zhao C, Sun M, Esbenshade TA, Brune ME, Fox GB, Schmidt M, Collins CA, Souers AJ, Iyengar R, Vasudevan A, Kym PR, Hancock AA, Rueter LE.

Eur J Pharmacol. 2006 Jul 1;540(1-3):115-20. Epub 2006 May 6.

PMID:
16765941
36.

Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.

Kym PR, Souers AJ, Campbell TJ, Lynch JK, Judd AS, Iyengar R, Vasudevan A, Gao J, Freeman JC, Wodka D, Mulhern M, Zhao G, Wagaw SH, Napier JJ, Brodjian S, Dayton BD, Reilly RM, Segreti JA, Fryer RM, Preusser LC, Reinhart GA, Hernandez L, Marsh KC, Sham HL, Collins CA, Polakowski JS.

J Med Chem. 2006 Apr 6;49(7):2339-52.

PMID:
16570930
37.
38.

Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.

Vasudevan A, Souers AJ, Freeman JC, Verzal MK, Gao J, Mulhern MM, Wodka D, Lynch JK, Engstrom KM, Wagaw SH, Brodjian S, Dayton B, Falls DH, Bush E, Brune M, Shapiro RD, Marsh KC, Hernandez LE, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5293-7. Epub 2005 Oct 3.

PMID:
16203136
39.

Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.

Kym PR, Iyengar R, Souers AJ, Lynch JK, Judd AS, Gao J, Freeman J, Mulhern M, Zhao G, Vasudevan A, Wodka D, Blackburn C, Brown J, Che JL, Cullis C, Lai SJ, LaMarche MJ, Marsilje T, Roses J, Sells T, Geddes B, Govek E, Patane M, Fry D, Dayton BD, Brodjian S, Falls D, Brune M, Bush E, Shapiro R, Knourek-Segel V, Fey T, McDowell C, Reinhart GA, Preusser LC, Marsh K, Hernandez L, Sham HL, Collins CA.

J Med Chem. 2005 Sep 22;48(19):5888-91.

PMID:
16161992
40.

Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists.

Vasudevan A, LaMarche MJ, Blackburn C, Che JL, Luchaco-Cullis CA, Lai S, Marsilje TH, Patane MA, Souers AJ, Wodka D, Geddes B, Chen S, Brodjian S, Falls DH, Dayton BD, Bush E, Brune M, Shapiro RD, Marsh KC, Hernandez LE, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4174-9.

PMID:
16085414
41.

Identification of aminopiperidine benzamides as MCHr1 antagonists.

Vasudevan A, Verzal MK, Wodka D, Souers AJ, Blackburn C, Che JL, Lai S, Brodjian S, Falls DH, Dayton BD, Govek E, Daniels T, Geddes B, Marsh KC, Hernandez LE, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3412-6.

PMID:
15950463
42.

Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.

Souers AJ, Gao J, Wodka D, Judd AS, Mulhern MM, Napier JJ, Brune ME, Bush EN, Brodjian SJ, Dayton BD, Shapiro R, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2752-7.

PMID:
15911251
43.

Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.

Souers AJ, Gao J, Brune M, Bush E, Wodka D, Vasudevan A, Judd AS, Mulhern M, Brodjian S, Dayton B, Shapiro R, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR.

J Med Chem. 2005 Mar 10;48(5):1318-21.

PMID:
15743174
44.

Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 3.

Souers AJ, Wodka D, Gao J, Lewis JC, Vasudevan A, Brodjian S, Dayton B, Ogiela CA, Fry D, Hernandez LE, Marsh KC, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4883-6.

PMID:
15341944
45.

Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2.

Vasudevan A, Wodka D, Verzal MK, Souers AJ, Gao J, Brodjian S, Fry D, Dayton B, Marsh KC, Hernandez LE, Ogiela CA, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4879-82.

PMID:
15341943
46.

Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1.

Souers AJ, Wodka D, Gao J, Lewis JC, Vasudevan A, Gentles R, Brodjian S, Dayton B, Ogiela CA, Fry D, Hernandez LE, Marsh KC, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.

PMID:
15341942
47.

Microwave-assisted C-H bond activation: a rapid entry into functionalized heterocycles.

Tan KL, Vasudevan A, Bergman RG, Ellman JA, Souers AJ.

Org Lett. 2003 Jun 12;5(12):2131-4.

PMID:
12790546
48.

Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production.

Kurukulasuriya R, Link JT, Madar DJ, Pei Z, Richards SJ, Rohde JJ, Souers AJ, Szczepankiewicz BG.

Curr Med Chem. 2003 Jan;10(2):123-53. Review.

PMID:
12570714
49.

Prospects for pharmacologic inhibition of hepatic glucose production.

Kurukulasuriya R, Link JT, Madar DJ, Pei Z, Rohde JJ, Richards SJ, Souers AJ, Szczepankiewicz BG.

Curr Med Chem. 2003 Jan;10(2):99-121. Review.

PMID:
12570713
50.

Supplemental Content

Loading ...
Support Center